Publication: American Journal of Managed Care
Dr. Houston Holmes discusses the delivery of CAR-T therapies in a community setting at the Community Oncology Alliance’s (COA) 2018 Community Oncology Conference.
With chimeric antigen receptor (CAR) T-cell therapy being so new, there is going to be a learning curve as providers become more educated about the treatments, the manufacturing process, and the toxicities, Houston Holmes, MD, MBA, FACP, a medical oncologist with Texas Oncology, explained at the Community Oncology Alliance’s (COA) 2018 Community Oncology Conference.
Read the full story at American Journal of Managed Care.